Mar 26 |
Virpax Pharmaceuticals Reports 2023 Year-End Results
|
Feb 7 |
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
|
Dec 29 |
Virpax Pharmaceuticals shareholders okay reverse stock split
|
Dec 29 |
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
|
Nov 17 |
Virpax Pharmaceuticals gets non-compliance notice from Nasdaq
|
Nov 17 |
Virpax Pharmaceuticals CEO and Chairman resigns on ongoing litigation
|
Nov 17 |
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
|
Nov 17 |
Virpax Pharmaceuticals Announces Leadership Transition
|
Nov 15 |
Virpax Pharmaceuticals GAAP EPS of -$0.51
|
Oct 31 |
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
|